With an impressive technological advancement over the period has added much more to the therapies for treatment of various diseases which has also led to introduction of cost effective protein fractioning technologies from plasma. This is also being seen as a major booster to the growth within the plasma therapy market during the forecast period. As per estimates by WHO about 108 million global blood donations come from the high-income countries, which is the home for 18% of the world’s population. Presence of favourable government initiates for the development of plasma derived medicine and rising awareness regarding the importance of blood donation are the key drivers for this market.
On the geographical forefront, North America is a leader held the market share in 2017 which is expected to sustain during the forecast period as well. This is mainly due to the growing number of hospitals and clinics which is increasing the demand for the plasma derived from proteins. They key driving forces expected to boost the market of plasma therapy in North America are rising awareness levels among the blood donors, presence of advanced protein fractioning procedures, and higher per capita income in the developed countries. Furthermore, APAC region is also considered to be fastest growing region mainly due to growing medical tourism, technological advancement, rising disposable income of the patients, rising healthcare practitioner’s awareness, and increasing government initiatives pertaining to the development of plasma protein medicines are expected to fuel the demand of plasma protein product. The report includes detailed market overview, market determinants, company profiling, sector analysis, market segmentation, geographical analysis, strategic recommendations, key company analysis, key findings, market estimations, market insights, analyst insights and predictive analysis of the market.
Key players of plasma therapy market include CSL limited, Telecris, Baxter, Grifols, Octapharma, Kedrion, and Chengdu Inst, Japan Red Cross, LFB group (France), Shanghai Blood Institute, BPL group (UK), and Sanquin.
The market study of plasma therapy market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analysing various regional players, regional tax laws and policies, consumer behaviour and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic Public Databases
Whitepapers, research-papers and news blogs
Company websites and their product catalogue.
Supplier Websites such as Alibaba, amazon for pricing analysis.
The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.
The Report Covers:
Comprehensive research methodology of global plasma therapy market
In-depth analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global plasma therapy market
Insights about market determinants which are stimulating the global plasma therapy market
Detailed and extensive market segments with regional distribution of forecasted revenues
Extensive profiles and recent developments of market players
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. Value Chain
2 Market Overview and Insights
2.2. Pricing Analysis
2.3. Analyst Insight & Current Market Trends
2.3.1. Key Findings
2.4.1. Regulations Related To Blood and Blood Components
2.4.2. Regulations On Clinical Trials
22.214.171.124. United States
126.96.36.199. European Union
2.4.3. Drug and Device Regulations
188.8.131.52. United States
184.108.40.206. European Union
2.5. Patent Analysis
3 Market Determinant
3.1.1. Growing Number of Neurological Patients Globally
3.1.2. Rising Disposable Income In the Developing Countries
3.1.3. Rising Cases of Arthiritis Globally
3.1.4. Rising Healthcare Expenditure and R&D In Stem Cell Prp For Cancer Treatment
3.1.5. Rise In Personalized Healthcare
3.2.1. High Cost of Plasma Therapy
3.2.2. Lack of Reimbursement Policies
3.3.1. Rising Cases Orthopaedic and Neurological Cases
3.3.2. Growing Application In Various Fields
3.3.3. Growing Medical Tourism In Emerging Countries
3.3.4. Rising Adoption of Prp In Sports Injuries
3.3.6. Developments In Other Fields of Regenerative Medicine
3.3.7. Restricted Use of Prp For Diabetic and Kidney Patients
4 Market Segmentation
4.1. Plasma Therapy By Source
4.2. Plasma Therapy By Application
220.127.116.11. Bone Repair and Regeneration
18.104.22.168. Chronic Tendinitis
4.2.2. Cardiac Muscle Injury
22.214.171.124. Androgenic Alopecia
126.96.36.199. Plastic Surgery
4.2.5. Nerve Injury
4.2.6. Other Applications
4.3. Plasma Therapy By Type
4.3.1. Leukocyte-Rich Fibrin
4.3.2. Pure Platelet-Rich Fibrin
4.3.3. Leukocyte-Rich Prp
4.3.4. Pure Prp
4.4. Plasma Therapy By End Users
4.4.1. Hospitals and Clinics
4.4.2. Research Institutes
5 Competitive Landscape
5.1. Key Company Analysis
5.2. Key Strategies
6 Regional Analysis
6.1. North America
6.1.1. United States
6.2.1. United Kingdom
6.2.6. Rest of the Europe
6.3. Asia Pacific
6.3.4. Rest of the Asia Pacific
6.4. Rest of the World
7 Company Profiles
7.1. Baxter International
7.2. Biolife Plasma Services
7.4. Bio Product Laboratory Ltd. (Bpl)
7.5. Cambryn Biologics Llc
7.6. Csl Ltd.
7.7. China Biologic Products, Inc.
7.8. Grifols International S.A.
7.9. Kedrion S.P.A.
7.10. Lfb Sa
7.12. Ge Healthcare
7.13. Arthrex Inc
7.14. Regen Lab
7.15. Tri-Star Technologies
- Baxter International
- Biolife Plasma Services
- Bio Product Laboratory Ltd. (Bpl)
- Cambryn Biologics Llc
- Csl Ltd.
- China Biologic Products, Inc.
- Grifols International S.A.
- Kedrion S.P.A.
- LFB SA
- Ge Healthcare
- Arthrex Inc
- Regen Lab
- Tri-Star Technologies